Mykola Stanislavchuk

Author

National Pirogov Memorial Medical University, Vinnytsya ORCID

Also Known As

Andriy Yagensky, M A Stanislavchuk, M Stanislavchuk, M. A. Stanislavchuk, M. Stanislavchuk, M.A. Stanislavchuk, Mykola A Stanislavchuk, Mykola A. Stanislavchuk, Mykola STANISLAVCHUK, Mykola Stanislavchuk

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

National Pirogov Memorial Medical University, Vinnytsya University of California San Diego Galapagos (Belgium)Western University Desert Medical Imaging

About

Mykola Stanislavchuk is an author at National Pirogov Memorial Medical University, Vinnytsya specializing in medicine, gastroenterology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.9K
2	Gastroenterology	3	3	346
3	Immunology	2	2	91
4	Clinical Nutrition	1	1	723
5	Diabetes	1	1	589

Mykola Stanislavchuk

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker, The Lancet Heart FailureIron MetabolismClinical NutritionAcute Heart FailureFerric Carboxymaltose	2020	723
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress, The Lancet UrologyRenal DiseaseRenal EventsRenal FunctionDiabetes	2019	589
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) Arthur Kavanaugh, Joel M. Kremer, L Ponce, Annals of the Rheumatic Diseases	2016	226
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial Brian G. Feagan, Bruce E. Sands, William J. Sandborn, The Lancet. Gastroenterology & hepatology Systemic TreatmentGolimumab MonotherapyGastroenterologyPathologyUlcerative Colitis	2023	208
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial Markus P. Schlaich, M Bellet, Michael A. Weber, The Lancet Molecular PharmacologyHypertensionResistant HypertensionCardiovascular DiseaseAntihypertensive Therapy	2022	206
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial Philip J. Mease, Laura C. Coates, Philip Helliwell, The Lancet	2018	202
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin, Gastroenterology	2023	86
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Marc Ferrante, Geert D’Haens, Vipul Jairath, The Lancet Moderately-to-severely Active CrohnImmunologyGastroenterologyClinical GastroenterologyUlcerative Colitis	2024	76
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn, Arthritis & Rheumatology	2017	75
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies David T. Rubin, Jessica R. Allegretti, Julián Panés, The Lancet Placebo-controlled InductionGastroenterologyPathologyClinical GastroenterologyGastrointestinal Pathology	2024	62

Page 1